SonoSite aims for expansion with $200m note offer:
This article was originally published in Clinica
Executive Summary
Hand-carried ultrasound specialist SonoSite (Bothell, Washington) is set to offer $200m worth of convertible senior notes, with the aim of funding the possible acquisition of complementary businesses or product lines. The proceeds may also be used for debt repayment, capital expenditure, investment in subsidiaries, or as additional working capital. The notes will pay interest twice a year, at a rate of 3.75% each year, and, in certain circumstances, will be convertible based on an initial conversion price of around $38.2 per share. SonoSite has granted the underwriters a 30-day option to buy up to $25m aggregate principal amount of additional notes.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.